standard paradigm for management of patients who present with concern for recurrence of brain metastases following initial stereotactic radiosurgery (SRS).
Ability to understand and the willingness to sign a written informed consent document.
Willingness to comply with all study procedures and availability for the duration of the study.
Age ≥18 years. Because no dosing or adverse event data are currently available on the use of SRS2, children are excluded from this study.
Karnofsky performance status ≥ 60.
Patients with brain metastases from hematologic malignancies due to significant differences in radiosensitivity and treatment paradigms.
Patients with psychiatric illness/social situations that would limit compliance with study requirements.
Postmenopausal (no menses in greater than or equal to 12 consecutive months).
History of hysterectomy or bilateral salpingo-oophorectomy.